Список литературы

Поставить закладку

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012;2:139-274. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN-Guideline-English.pdf
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4S):S1-S276. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf
Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30(5):621-31. doi: 10.1016/s0272-6386(97)90485-6
Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996;27:647-51. doi: 10.1016/s0272-6386(96)90098-0
Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 2017;12(3):502-517. doi: 10.2215/CJN.05960616
Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol 2015;11(2):76-87. doi: 10.1038/nrneph.2014.216
McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010;5(11):2115-21. doi: 10.2215/CJN.03800609
Candelier JJ, Lorenzo HK. Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle. Cell Tissue Res 2020;379(2):231-243. doi: 10.1007/s00441-019-03147-y
Abdi R, Dong VM, Rubel JR et al. Correlation between glomerular size and long-term renal function in patients with substantial loss of renal mass. J Urol 2003;170(1):42-4. doi: 10.1097/01.ju.0000069821.97385.6b
D"Agati VD, Chagnac A, de Vries APJ et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol 2016;12(8):453-71. doi: 10.1038/nrneph.2016.75
Cunningham EE, Zielezny MA, Venuto RC. Heroin-associated nephropathy. A nationwide problem. JAMA 1983;250(21):2935-6
Barri YM, Munshi NC, Sukumalchantra S et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004;65(2):634-41. doi: 10.1111/j.1523-1755.2004.00426.x
Dressler D, Wright JR, Houghton JB, Kalra PA. Another case of focal segmental glomerulosclerosis in an acutely uraemic patient following interferon therapy. Nephrol Dial Transplant 1999;14(8):2049-50. doi: 10.1093/ndt/14.8.2049
Herlitz LC, Markowitz GS, Farris AB et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol 2010;21(1):163-72. doi: 10.1681/ASN.2009040450
Santella RN, Rimmer JM, MacPherson BR. Focal segmental glomerulosclerosis in patients receiving lithium carbonate. Am J Med 1988;84(5):951-4. doi: 10.1016/0002-9343(88)90077-0
Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis 2013;61(5):778-81. doi: 10.1053/j.ajkd.2012.08.048
Meehan SM, Pascual M, Williams WW et al. De novo collapsing glomerulopathy in renal allografts. Transplantation 1998;65(9):1192-7. doi: 10.1097/00007890-199805150-00009
Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005;353(19):2088-9. doi: 10.1056/NEJM200511103531922
Malone AF, Phelan PJ, Hall G et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int 2014;86(6):1253-9. doi: 10.1038/ki.2014.305
Hinkes BG, Mucha B, Vlangos CN et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007;119(4):e907-19. doi: 10.1542/peds.2006-2164
Boyer O, Benoit G, Gribouval O et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011;22(2):239-45. doi: 10.1681/ASN.2010050518
Rivera F, López-Gómez JM, Pérez-García R, Spanish Registry of Glomerulonephritis. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004;66(3):898-904. doi: 10.1111/j.1523-1755.2004.00833.x
Hommos MS, De Vriese AS, Alexander MP et al. The incidence of primary vs secondary focal segmental glomerulosclerosis: a clinicopathologic study. Mayo Clin Proc 2017;92(12):1772-1781. doi: 10.1016/j.mayocp.2017.09.011
Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004;44(5):815-25
Yao T, Udwan K, John R et al. Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS. Clin J Am Soc Nephrol 2019;14(2):213-223. doi: 10.2215/CJN.08750718
Хроническая болезнь почек (ХБП). Клинические рекомендации. 2021 год. https://cr.minzdrav.gov.ru/recomend/469_2
Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006
Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55(4):622-7. doi: 10.1053/j.ajkd.2010.02.337
D"Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;43(2):368-82. doi: 10.1053/j.ajkd.2003.10.024
De Vriese AS, Sethi S, Nath KA et al. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol 2018; 29(3):759-774. doi: 10.1681/ASN.2017090958
Rao TKS. Renal complications in HIV disease. Med Clin North Am 1996;80(6):1437-51
Winston JA, Burns GC, Klotman PE. The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy. Semin Nephrol 1998;18(4):373-7
Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002;62(6):2301-10. doi: 10.1046/j.1523-1755.2002.00674.x
Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15(8):2169-77. doi: 10.1097/01.ASN.0000135051.62500.97
Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995;25(4):534-42. doi: 10.1016/0272-6386(95)90120-5
Thomas DB, Franceschini N, Hogan SL et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006;69(5):920-6. doi: 10.1038/sj.ki.5000160
Sethi S, Zand L, Nasr SH et al. Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. Clin Kidney J 2014; 7(6):531-7. doi: 10.1093/ckj/sfu100
Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59(4):1498-509. doi: 10.1046/j.1523-1755.2001.0590041498.x
Praga M, Morales E, Herrero JC et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999;33(1):52-8. doi: 10.1016/s0272-6386(99)70257-x
Chagnac A, Weinstein T, Herman M et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14(6):1480-6. doi: 10.1097/01.asn.0000068462.38661.89
Lepori N, Zand L, Sethi S et al. Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. Clin Kidney J 2018;11(2):179-190. doi: 10.1093/ckj/sfx143
Caridi G, Bertelli R, Carrea A et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 2001;12(12):2742-6
Ashraf S, Kudo H, Rao J et al. Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nat Commun 2018;17;9(1):1960. doi: 10.1038/s41467-018-04193-w
Нефрология. Клинические рекомендации. По ред. Шилов ЕМ, Смирнов АВ, Козловская НЛ. ГОЭТАР-Медиа, 2016
Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis. 2020 Aug 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan
Yuan YD, Gong XW, Yang YH. Meta-analysis of risk factors for recurrent pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2012;92(34):2419-25
Leslom AN, Alrawiah ZMS, Al-Asmari AMA at al. Prevalence of pulmonary thromboembolism in nephrotic syndrome patients: A systematic review and meta-analysis. J Family Med Prim Care 2020;9(2):497-501. doi: 10.4103/jfmpc.jfmpc_1076_19
Li SJ, Tu YM, Zhou CS, Zhang LH, Liu ZH. Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome. Clin Exp Nephrol 2016;20(2):212-7. doi: 10.1007/s10157-015-1149-4
Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroidresistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56(6):2220-6. doi: 10.1046/j.1523-1755.1999.00778.x
Ramachandran R, Kumar V, Rathi M et al. Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Nephrol Dial Transplant 2014;29(10):1918-24. doi: 10.1093/ndt/gfu097
Meyrier A, Noel LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 1994;45(5):1446-56. doi: 10.1038/ki.1994.189
Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991;35 Suppl 1:S37-42
Ghiggeri GM, Catarsi P, Scolari F et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther 2004;26(9):1411-8. doi: 10.1016/j.clinthera.2004.09.012
Segarra A, Vila J, Pou L et al. Combined therapy of tacrolimus and corticosteroids in cyclosporinresistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002;17(4):655-62. doi: 10.1093/ndt/17.4.655
Gulati F, Sinha F, Gupta F et al. Treatment with tacrolimus and prednisolone ispreferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistantnephrotic syndrome. Кidney International 2012;82:1130-1135. doi:10.1038/ki.2012.238
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:1-150
Gyamlani G, Molnar MZ, Lu JL et al. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrology Dialysis Transplantation 2017;32(1):157-164. doi: 10.1093/ndt/gfw227
Zhang LJ, Zhang Z, Li SJ et al. Pulmonary embolism and renal vein thrombosis in patients with nephrotic syndrome: prospective evaluation of prevalence and risk factors with CT. Radiology 2014;273(3):897-906. doi: 10.1148/radiol.14140121
Avasthi P, Greene E, Scholler C, Fowler C. Noninvasive diagnosis of renal vein thrombosis by ultrasonic echo-Doppler flowmetry. Kidney International 1983;23:882-887
Rodríguez MTJ, Utiel FJB, Hinojosa JB, Pérez del Barrio MP. Development of deep vein thrombosis during treatment with plasmapheresis. Nefrologia 2017;37(2):115-228. doi: 10.1016/j.nefroe.2017.04.007
Laurin LP, Nachman PH, Foster BJ. Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis of the Literature. Can J Kidney Health Dis 2017;4:2054358117692559. doi: 10.1177/2054358117692559
Chiou Y-Y, Lee Y-C, Chen M-J. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis. Curr Med Res Opin 2017;33(8):1389-1399. doi: 10.1080/03007995.2017.1322567
Okpechi IG, Ameh OI, Bello AK et al. Epidemiology of Histologically Proven Glomerulonephritis in Africa: A Systematic Review and Meta-Analysis. PLoS One 2016;11(3):e0152203. doi: 10.1371/journal.pone.0152203
D"Agati VD, Alster JM, Jennette JC et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clinical Journal of the American Society of Nephrology 2013;8(3):399-406
Fuiano G, Comi N, Magri P et al. Serial morphometric analysis of sclerotic lesions in primary "focal" segmental glomerulosclerosis. J Am Soc Nephrol 1996;7(1):49-55
Fogo A, Glick AD, Horn SL, Horn RG. Is focal segmental glomerulosclerosis really focal? Distribution of lesions in adults and children. Kidney Int 1995;47(6):1690-6. doi: 10.1038/ki.1995.234
Laurin LP, Gasim AM, Derebail VK et al. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. Clin J Am Soc Nephrol 2016;11(10):1752-1759
Ponticelli C, Villa M, Banfi G et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999;34(4):618-625. doi: 10.1016/S0272-6386(99)70384-7
Ekrikpo UE, Obiagwu PN, Udo AI etal. Prevalence and distribution of primary glomerular diseases in Africa: a systematic review and meta-analysis of observational studies. Pan Afr Med J 2023;45:153. doi: 10.11604/pamj.2023.45.153.40741
Ishizuka K, Miura K, Hashimoto T et al. Degree of foot process effacement in patients with genetic focal segmental glomerulosclerosis: a single-center analysis and review of the literature. Sci Rep 2021;11(1):12008. doi: 10.1038/s41598-021-91520-9
Deegens JK, Dijkman HB, Borm GF et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 2008;74:1568-1576
van den Berg JG, van den Bergh Weerman MA, Assmann KJ et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004;66(5):1901-6. doi: 10.1111/j.1523-1755.2004.00964.x
Schwartz MM, Korbet SM. Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis. Am J Kidney Dis 1993;22(6):874-83
D"Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003;23(2):117-34. doi: 10.1053/snep.2003.50012
Gast C, Pengelly RJ, Lyon M et al. Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 2016;31:961-970
Santín S, Bullich G, Tazón-Vega B et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011;6:1139-1148
Tato AM, Carrera N, García-Murias M et al. Genetic testing in focal segmental glomerulosclerosis: in whom and when? Clin Kidney J 2023;16(11):2011-2022
Nagano C, Hara S, Yoshikawa N et al. Clinical, Pathological, and Genetic Characteristics in Patients with Focal Segmental Glomerulosclerosis. Kidney360 2022;3(8):1384-1393
Ogino D, Hashimoto T, Hattori M et al. Analysis of the genes responsible for steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis in Japanese patients by whole-exome sequencing analysis. J Hum Genet 2016;61:137-141
McCarthy HJ, Bierzynska A, Wherlock M et al. Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2013;8:637-648
Lu L, Wan H, Yin Y et al. The p.R229Q variant of the NPHS2 (podocin) gene in focal segmental glomerulosclerosis and steroid-resistant nephrotic syndrome: a meta-analysis. Int Urol Nephrol 2014;46(7):1383-93. doi: 10.1007/s11255-014-0676-3
Sadowski CE, Lovric S, Ashraf S et al. A single-gene cause in 29.5% of cases of steroidresistant nephrotic syndrome. J Am Soc Nephrol 2015;26(6):1279-89. doi: 10.1681/ASN.2014050489
Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol 2012;23(11):1769-76. doi: 10.1681/ASN.2012040389
Xie X, Liu Y, Perkovic V et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 2016;67(5):728-741
Geng DF, Sun WF, Yang L et al. Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials. J Renin Angiotensin Aldosterone Syst 2014;15(1):44-51. doi: 10.1177/1470320312474054
Campbell KN, Pennese N, Zaffalon A et al. Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis. Kidney Med 2022;4(5):100457. doi: 10.1016/j.xkme.2022.100457
Proesmans W, Van Dyck M, Devriendt K. Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment. Nephrol Dial Transplant 2009;24(4):1335-8. doi:10.1093/ndt/gfn725
Daina E, Cravedi P, Alpa M et al. A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study. Nephron 2015;130(1):13-20. doi: 10.1159/000381480
Medjeral-Thomas N, Ziaj S, Condon M et al. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol 2014;9(3):478-83. doi: 10.2215/CJN.07190713
Rostoker G, Durand-Zaleski I, Petit-Phar M et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. Nephron 1995;69(1):20-8. doi: 10.1159/000188355
Kelddal S, Nykjær KM, Gregersen JW et al. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications. BMC Nephrol 2009;20:139. doi: 10.1186/s12882-019-1336-8
Welander F, Holmberg H, Dimeny E et al. Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome – A retrospective observational study. PLoS ONE 2021;16(7):e0255009
Matyjek A, Rymarz A, Nowicka Z et al. Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome – A Single Center Prospective Study. J Clin Med 2021;10:5709. doi: 10.3390/jcm10235709
Ha JT, Neuen BL, Cheng LP et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2019;171(3):181-189. doi: 10.7326/M19-0087
Chen HY, Ou SH, Huang CW et al. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. Clin Drug Investig 2021;41(4):341-351. doi: 10.1007/s40261-021-01016-7
Tijani A, Coons EM, Mizuki B et al. Direct Oral Anticoagulants Versus Warfarin for Venous Thromboembolism Prophylaxis in Patients With Nephrotic Syndrome: A Retrospective Cohort Study. Ann Pharmacother 2023;57(7):787-794. doi: 10.1177/10600280221129348
Van Meerhaeghe T, Cez A, Dahan K et al. Apixaban Prophylactic Anticoagulation in Patients With Nephrotic Syndrome. doi:10.21203/rs.3.rs-730015/v1
Troyanov S, Wall CA, Miller JA et al. Focal and Segmental Glomerulosclerosis: Definition and Relevance of a Partial Remission. J Am Soc Nephrol 2005;16(4):1061-8. doi: 10.1681/ASN.2004070593
Goumenos DS, Tsagalis G, El Nahas AM et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron Clin Pract 2006;104(2):c75-82. doi: 10.1159/000093993
Laurin LP, Gasim AM, Poulton CJ et al. Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. Clin J Am Soc Nephrol 2016;11(3):386-94. doi: 10.2215/CJN.07110615
Braun N, Schmutzler F, Lange C et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 2008;2008(3):CD003233. doi: 10.1002/14651858.CD003233.pub2
Chávez-Mendoza CA, Niño-Cruz JA, Correa-Rotter R et al. Calcineurin Inhibitors With Reduced-Dose Steroids as First-Line Therapy for Focal Segmental Glomerulosclerosis. Kidney Int Rep 2018;4(1):40-47. doi: 10.1016/j.ekir.2018.08.010
Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56(6):2220-2226
Duncan N, Dhaygude A, Owen J et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004;19(12):3062-7. doi: 10.1093/ndt/gfh536
Li HY, Zhang X, Zhou T et al. Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis. BMC Nephrol 2019;20(1):384. doi: 10.1186/s12882-019-1575-8
Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 2022;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3
Ren H, Shen P, Li X et al. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. Am J Nephrol 2013;37(1):84-90. doi: 10.1159/000346256
Ramachandran R, Kumar V, Rathi M et al. Tacrolimus therapy in adult-onset steroidresistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Nephrol Dial Transplant 2014;29(10):1918-24. doi: 10.1093/ndt/gfu097
Hogg RJ, Friedman A, Greene T et al. Renal function and proteinuria after successful immunosuppressivetherapies in patients with FSGS. Clin J Am Soc Nephrol 2013;8:211-218
Gipson DS, Trachtman H, Kaskel FJ et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80:868-87
Plank C, Kalb V, Hinkes B et al. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicenter trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol 2008;23:1483-1493
Cattran D, Neogi T, Sharma R et al. Serial estimates of serum permeability activity and clinical correlate in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 2003;14:448-453
Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol 2020;21(1):134. doi: 10.1186/s12882-020-01797-7
Martinelli R, Pereira LJ, Silva OMM et al. Cyclophosphamide in the treatment of focal segmental glomerulosclerosis. Braz J Med Biol Res 2004;37(9):1365-72.doi: 10.1590/s0100-879x2004000900011
Saca E, Hazza I. Cyclosporine-a therapy in steroid dependent nephrotic syndrome: experience in amman, jordan. Saudi J Kidney Dis Transpl 2002;13(4):520-3
Gorsane I, Helal I, Yacoub I et al. Cyclosporine therapy in steroid-dependent or steroid-resistant idiopathic focal and segmental glomerulosclerosis. Saudi J Kidney Dis Transpl 2016;27(5):958-965. doi: 10.4103/1319-2442.190864
Cheng X, Bo Y, Jing X et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clinical Kidney Journal 2021;14(4):1042-1054. doi: 10.1093/ckj/sfaa191
Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol 2011;76(2):151-8. doi: 10.5414/cn107092
Dekkers MJ, Groothoff JW, Zietse R, Betjes MG. A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood. BMC Res Notes 2015;8:266. doi: 10.1186/s13104-015-1255-0
Ruggenenti P, Ruggiero B, Cravedi P et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 2014;25(4):850-63. doi: 10.1681/ASN.2013030251
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4):753-779. doi: 10.1016/j.kint.2021.05.015
Ha T-S. Circulating Permeability Factors in Idiopathic Nephrotic Syndrome. Child Kidney Dis 2019;23(1):7-21. doi: 10.3339/jkspn.2019.23.1.7
Chitalia VC, Wells JE, Robson RA et al. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999;56(6):2236-42
Deegens JK, Assmann KJ, Steenbergen EJ et al. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth J Med 2005;63(10):393-8
Beaman M, Howie AJ, Hardwicke J et al. The glomerular tip lesion: a steroid responsive nephrotic syndrome. Clin Nephrol 1987;27(5):217-21
Pei Y, Cattran D, Delmore T et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 1987;82(5):938-44. doi: 10.1016/0002-9343(87)90155-0
Banfi G, Moriggi M, Sabadini E et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991;36(2):53-9
Somaili M, Wang C, Almansour O et al. Superior mesenteric vein thrombosis in a patient with primary focal segmental glomerulosclerosis: A case report. Medicine Case Reports and Study Protocols 2(12):p e0199, December 2021. | doi: 10.1097/MD9.0000000000000199